AR044732A1 - Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica - Google Patents
Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeuticaInfo
- Publication number
- AR044732A1 AR044732A1 ARP020104293A ARP020104293A AR044732A1 AR 044732 A1 AR044732 A1 AR 044732A1 AR P020104293 A ARP020104293 A AR P020104293A AR P020104293 A ARP020104293 A AR P020104293A AR 044732 A1 AR044732 A1 AR 044732A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- appropriate
- benigan
- prostata
- hyperplasia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Composición farmacéutica que cada 1 ml contiene: Polisacáridos de Gérmenes Gram Negativos: entre 0,05 gr. y 0,002 gr.; Timo (extracto hidrosoluble): entre 2 mg. y 0,1 mg.; Próstata (extracto hidrosoluble): entre 1 mg. y 0,01 mg.; Carbohidrato totales (glucosa): entre 2 mg. y 0,02 mg.; Solución Fisiológica estéril: c.s.p 1 ml.; método de preparación de la composición indicada, que comprende un método apropiado para cultivar bacterias del género Pseudomona en las siguientes condiciones: a) el cultivo del referido polisacárido se realiza en un medio líquido del mismo modo especializado como se lo hace habitualmente, recordando siempre que se debe trabajar en condiciones rigurosas de asepsia bacteriológica; b) se debe disponer de una cepa apropiada, la cual deberá ser tipificada previamente mediante las pruebas bioquímicas correspondientes: La aplicación de la composición indicada, en dosis adecuadas, para el tratamiento de la Hiperplásica Benigna de la Próstata.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP020104293A AR044732A1 (es) | 2002-11-08 | 2002-11-08 | Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica |
AT03024296T ATE338560T1 (de) | 2002-11-08 | 2003-10-23 | Pharmazeutische zusammentsetzung zur medizinischen behandlung von gutartiger prostathyperplasie, dessen vorbereitungsmethode und dessen therapeutische verwendung |
ES03024296T ES2272875T3 (es) | 2002-11-08 | 2003-10-23 | Una composicion farmaceutica para el tratamiento medico de la hiperplasia benigna de la prostata, su metodo de preparacion y su aplicacion terapeutica. |
EP03024296A EP1417969B1 (en) | 2002-11-08 | 2003-10-23 | A pharmaceutical composition for the medical treatment of the benign prostatic hyperplasia, its preparation method and its therapeutical application |
US10/697,264 US20040131694A1 (en) | 2002-11-02 | 2003-10-31 | Pharmaceutical composition for the medical treatment of the benign prostatic hyperplasia, its preparation method and its therapeutic application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP020104293A AR044732A1 (es) | 2002-11-08 | 2002-11-08 | Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica |
Publications (1)
Publication Number | Publication Date |
---|---|
AR044732A1 true AR044732A1 (es) | 2005-10-05 |
Family
ID=32097251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104293A AR044732A1 (es) | 2002-11-02 | 2002-11-08 | Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040131694A1 (es) |
EP (1) | EP1417969B1 (es) |
AR (1) | AR044732A1 (es) |
AT (1) | ATE338560T1 (es) |
ES (1) | ES2272875T3 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR055311A1 (es) | 2006-02-17 | 2007-08-15 | H P B S A | Composicion farmaceutica solida para el tratamiento de la hiperplasia benigna de prostata, procedimiento para su elaboracion y metodo de tratamiento |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1339308C (en) * | 1987-06-18 | 1997-08-19 | Koichi Niimura | Polysaccharides and antiviral drug containing polysaccharides as active ingredient |
US5763429A (en) * | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
US5972615A (en) * | 1998-01-21 | 1999-10-26 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
DE69937564T2 (de) * | 1998-08-03 | 2008-10-23 | Ronald E. Sarasota Wheeler | Prostata- formulierung |
US6200573B1 (en) * | 1999-12-03 | 2001-03-13 | Starcor Pharmaceuticals, Inc. | Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia |
IT1320180B1 (it) * | 2000-12-29 | 2003-11-26 | Hunza Di Marazzita Maria Carme | Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e |
KR20070008625A (ko) * | 2004-04-05 | 2007-01-17 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
US20060003950A1 (en) * | 2004-06-30 | 2006-01-05 | Bone Care International, Inc. | Method of treating prostatic diseases using a combination of vitamin D analogues and other agents |
-
2002
- 2002-11-08 AR ARP020104293A patent/AR044732A1/es unknown
-
2003
- 2003-10-23 EP EP03024296A patent/EP1417969B1/en not_active Expired - Lifetime
- 2003-10-23 ES ES03024296T patent/ES2272875T3/es not_active Expired - Lifetime
- 2003-10-23 AT AT03024296T patent/ATE338560T1/de not_active IP Right Cessation
- 2003-10-31 US US10/697,264 patent/US20040131694A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2272875T3 (es) | 2007-05-01 |
EP1417969B1 (en) | 2006-09-06 |
ATE338560T1 (de) | 2006-09-15 |
US20040131694A1 (en) | 2004-07-08 |
EP1417969A1 (en) | 2004-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rowen et al. | A plausible “penny” costing effective treatment for corona virus-ozone therapy | |
Wainwright | Photodynamic antimicrobial chemotherapy (PACT). | |
DE60107065D1 (de) | Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut | |
Hu et al. | Preparation and in vivo. Antitumor activity of κ-carrageenan oligosaccharides | |
AR042795A1 (es) | Fluidos de dialisis biocompatibles que contienen icodextrinas | |
NO332893B1 (no) | Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi | |
Gardeva et al. | Cancer protective action of polysaccharide, derived from red microalga Porphyridium cruentum—a biological background | |
Braun-Falco et al. | Leucine aminopeptidase activity in mast cells | |
Mori et al. | Photodynamic therapy for experimental tumors using ATX‐S10 (Na), a hydrophilic chlorin photosensitizer, and diode laser | |
CN115212243B (zh) | 淫羊藿提取物的应用 | |
Vogel et al. | γ-L-Glutaminyl-4-hydroxybenzene, an inducer of cryptobiosis in Agaricus bisporus and a source of specific metabolic inhibitors for melanogenic cells | |
CN102210699A (zh) | 壳寡糖在制备防治心脑血管疾病药物中的应用 | |
AR044732A1 (es) | Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica | |
Jakopovich | New dietary supplements from medicinal mushrooms: Dr Myko San—a registration report | |
Ma et al. | Combination sonodynamic therapy with immunoadjuvant may be a promising new modality for cancer treatment | |
Jagetia et al. | Treatment with Alstonia scholaris enhances radiosensitivity in vitro and in vivo | |
Liu et al. | Study of cell killing and morphology on S180 by ultrasound activating hematoporphyrin derivatives | |
CN100348209C (zh) | 天然番茄红素复合油制剂和胶囊及其制备方法和用途 | |
González et al. | Rethinking vitamin C and cancer: an update on nutritional oncology | |
Khalikova et al. | Regulation of activity of cathepsins B, L, and D in murine lymphosarcoma model at a combined treatment with cyclophosphamide and yeast polysaccharide | |
SE0301577L (sv) | Lösning med låg natriumhalt | |
Pannu et al. | The green blood” wheatgrass juice, a health tonic having antibacterial potential | |
JPH10298099A (ja) | 細胞賦活組成物 | |
Ojewole | P-2: Hypotensive effect of Leonotis leonurus aqueous leaf extract in rats | |
Sarfraz | H16 Arsenic to biologics: psoriasis treatment through the ages |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |